Common Contracts
12 similar Underwriting Agreement contracts by Zoe's Kitchen, Inc., Abm Industries Inc /De/, Auris Medical Holding AG, others
7,016,312 Shares of Common Stock Pre-Funded Warrants to Purchase Up to 3,483,688 Shares of Common Stock ($0.001 par value per share) KalVista Pharmaceuticals, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • February 16th, 2024 • KalVista Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
LUCID DIAGNOSTICS INC. [NUMBER OF SHARES] Shares of Common Stock (par value $0.001 per share) Underwriting AgreementUnderwriting Agreement • October 8th, 2021 • Lucid Diagnostics Inc. • Surgical & medical instruments & apparatus • New York
Lucid Diagnostics Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of [●] shares of its common stock, par value $0.001 per share (the “Shares”). The [●] Shares to be sold by the Company are called the “Firm Shares.” In addition, the Company has granted to the Underwriters an option to purchase up to an additional [●] Shares. The additional [●] Shares to be sold by the Company pursuant to such option are collectively called the “Option Shares.” The Firm Shares and, if and to the extent such option is exercised, the Option Shares, are collectively called the “Offered Shares.” Cantor Fitzgerald & Co. (“Cantor”) and Canaccord Genuity LLC (“Canaccord”) have agreed to act as representatives of the several Underwriters (in such capacity, the “Representatives”) in connection with the offering and sale of the Offered Shares.
BRAINSWAY LTD. 4,622,000 American Depositary Shares Representing an Aggregate of 9,244,000 Ordinary Shares (par value NIS 0.04 per share) Underwriting AgreementUnderwriting Agreement • February 25th, 2021 • Brainsway Ltd. • Surgical & medical instruments & apparatus • New York
The ADSs will be evidenced by American Depositary Receipts (“ADRs”) issued pursuant to that certain Deposit Agreement to be dated on or prior to April 22, 2019 (the “Deposit Agreement”), by and among the Company, The Bank of New York Mellon, as depositary (the “Depositary”), and all holders and beneficial owners of ADSs issued thereunder. The Company shall, following subscription by the Underwriters of the Offered Shares pursuant to this Agreement, deposit, on behalf of the Underwriters, the Ordinary Shares being delivered in the form of the Offered Shares with Bank Leumi as custodian (the “Custodian”) for the Depositary, which shall deliver the Offered Shares to the Representative for the account of the several Underwriters for subsequent delivery to the other several Underwriters or the investors, as the case may be. Unless the context otherwise requires, each reference to the Offered Shares or ADSs herein also includes the Ordinary Shares and the ADRs evidencing such ADSs.
CASSAVA SCIENCES, INC. 9,375,000 Shares of Common Stock (par value $0.001 per share) Underwriting AgreementUnderwriting Agreement • November 13th, 2020 • Cassava Sciences Inc • Pharmaceutical preparations • New York
9,090,909 Shares Progenics Pharmaceuticals, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • August 10th, 2018 • Progenics Pharmaceuticals Inc • Pharmaceutical preparations • New York
● make any demand for, or exercise any right with respect to, the registration under the Securities Act of the offer and sale of any Shares or Related Securities, or cause to be filed a registration statement, prospectus or prospectus supplement (or an amendment or supplement thereto) with respect to any such registration, or
9,047,741 Shares of Common Stock ABM Industries Incorporated UNDERWRITING AGREEMENTUnderwriting Agreement • March 19th, 2018 • Abm Industries Inc /De/ • Services-to dwellings & other buildings • New York
Introductory. Certain stockholders of ABM Industries Incorporated, a Delaware corporation (the “Company”), named in Schedule A (collectively, the “Selling Stockholders”) propose to sell to the several underwriters named in Schedule B (the “Underwriters”) an aggregate of 9,047,741 shares of the Company’s common stock, par value $0.01 per share (the “Shares”). The 9,047,741 Shares to be sold by the Selling Stockholders are collectively called the “Offered Shares.” Goldman Sachs & Co. LLC (“GS”) and UBS Securities LLC (“UBS”) have agreed to act as representatives of the several Underwriters (in such capacity, the “Representatives”) in connection with the offering and sale of the Offered Shares. To the extent there are no additional underwriters listed on Schedule B, the term “Representatives” as used herein shall mean you, as Underwriters, and the term “Underwriters” shall mean either the singular or the plural, as the context requires.
Erytech Pharma S.A. [Number of Shares] Ordinary Shares and [Number of ADSs] American Depositary Shares Each Representing One Ordinary Share (Nominal Value €0.10 Per Share) UNDERWRITING AGREEMENTUnderwriting Agreement • November 8th, 2017 • Erytech Pharma S.A. • Biological products, (no disgnostic substances) • New York
● ] Common Shares Auris Medical Holding AG UNDERWRITING AGREEMENTUnderwriting Agreement • May 4th, 2015 • Auris Medical Holding AG • Pharmaceutical preparations • New York
Die Unterzeichnende verpflichtet sich hiermit bedingungslos, eine dem Ausgabebetrag entsprechende Einlage der gezeichneten Aktien zu leisten.
FORM OF UNDERWRITING AGREEMENTUnderwriting Agreement • November 12th, 2014 • Zoe's Kitchen, Inc. • Retail-eating places • New York
FORM OF UNDERWRITING AGREEMENTUnderwriting Agreement • August 11th, 2014 • Zoe's Kitchen, Inc. • Retail-eating places • New York
3,692,673 Shares Comstock mining inc. Common Stock, $0.000666 par value UNDERWRITING AGREEMENTUnderwriting Agreement • November 19th, 2012 • Comstock Mining Inc. • Gold and silver ores • New York
The undersigned is an owner of record or beneficially of certain shares of common stock, par value $.000666 per share, of the Company (“Shares”) or securities convertible into or exchangeable or exercisable for Shares. The Company proposes to carry out a public offering of Shares (the “Offering”) for which you will act as the representative of the underwriters (in such capacity, the “Representative”). The undersigned recognizes that the Offering will be of benefit to the undersigned and will benefit the Company by, among other things, raising additional capital for its operations. The undersigned acknowledges that you and the other underwriters are relying on the representations and agreements of the undersigned contained in this letter agreement in carrying out the Offering and in entering into underwriting arrangements with the Company with respect to the Offering.
16,000,000 Shares BioSante Pharmaceuticals, Inc. Common Stock, $0.0001 Par Value per Share UNDERWRITING AGREEMENTUnderwriting Agreement • July 28th, 2011 • Biosante Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
Introductory. BioSante Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of 16,000,000 shares of its common stock, par value $0.0001 per share (the “Common Stock”). The 16,000,000 shares of Common Stock to be sold by the Company are collectively called the “Firm Shares.” In addition, the Company has granted to the Underwriters an option to purchase up to an additional 2,400,000 shares of Common Stock as provided in Section 2. The additional 2,400,000 shares of Common Stock to be sold by the Company pursuant to such option are collectively called the “Optional Shares.” The Firm Shares and, if and to the extent such option is exercised, the Optional Shares are collectively called the “Offered Shares.” Jefferies & Company, Inc. (“Jefferies”) has agreed to act as representative of the several Underwriters (in such capacity, the “Representative”) in connection with the o
